Home Applications 219407 Application 219407
Type NDA
Sponsor IONIS PHARMS INC Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 DAWNZERA (AUTOINJECTOR) DONIDALORSEN SODIUM SOLUTION;SUBCUTANEOUS EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N219407-001 DAWNZERA (AUTOINJECTOR) DONIDALORSEN SODIUM EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21
Orange Book patents# Current patent rows page 1 of 1 · 5 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N219407-001 9315811 2032-10-21 U-3010 2025-09-16 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 1 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N219407-001 ODE-550 2032-08-21
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N219407-001 DAWNZERA (AUTOINJECTOR) EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219407-001 DAWNZERA (AUTOINJECTOR) EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219407-001 DAWNZERA (AUTOINJECTOR) EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 DAWNZERA (AUTOINJECTOR) EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21 31067a03dcf5…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 DAWNZERA (AUTOINJECTOR) EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) SOLUTION / SUBCUTANEOUS RLD, RS 2025-08-21 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N219407-001 9315811 2032-10-21 U-3010 2025-09-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219407-001 9315811 2032-10-21 U-3010 2025-09-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219407-001 9315811 2032-10-21 U-3010 2025-09-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 9315811 2032-10-21 U-3010 2025-09-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16 31067a03dcf5…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 9315811 2032-10-21 U-3010 2025-09-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 9127276 2034-05-01 Drug substance 2025-09-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 9181549 2034-05-01 Drug substance 2025-09-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 9670492 2034-08-28 Drug substance 2025-09-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 10294477 2035-05-01 U-3010 Drug substance, Drug product 2025-09-16 a50c72e98297…
Observed Orange Book exclusivity history# Captured, Edition, Application-product table Captured Edition Application-product Exclusivity code Expiration Source SHA-256 2026-09-14 22:38:34 2026-08 N219407-001 ODE-550 2032-08-21 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219407-001 ODE-550 2032-08-21 caaa826d4ba7…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219407-001 ODE-550 2032-08-21 a50c72e98297…
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join DAWNZERA DONIDALORSEN Ionis Pharmaceuticals Inc. 3ff501e0-f75f-07da-e063-6294a90a0cb7 2025-09-24 Warnings, Adverse reactions Exact identifier application applno (NDA): 219407 application number: NDA219407
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Documents# Document, Submission type, Date table Document Submission type Date 83629 ORIG 2025-10-02 83207 ORIG 2025-08-27 83170 ORIG 2025-08-22